<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35069924</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1869-3474</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nuclear medicine and molecular imaging</Title><ISOAbbreviation>Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Abnormality Pattern of F-18 FDG PET Whole Body with Functional MRI Brain in Post-Acute COVID-19.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>41</EndPage><MedlinePgn>29-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13139-021-00730-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">The study aimed to investigate imaging abnormalities associated with post-acute COVID-19 using F-18 FDG PET/CT and PET/ rsfMRI brain.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We retrospectively recruited 13 patients with post-acute COVID-19. The post-acute COVID-19 symptoms and neuropsychiatric tests were performed before F-18 FDG PET/CT whole body with PET/rsfMRI brain. Qualitative and semiquantitative analyses were also conducted in both whole body and brain images.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 13 patients, 8 (61.5%) had myositis, followed by 8 (61.5%) with vasculitis (mainly in the thoracic aorta), and 7 (53.8%) with lung abnormalities.. Interestingly, one patient with a very high serum RBD IgG antibody demonstrated diffuse myositis throughout the body which potentially associated with immune-mediated myositis. One patient experienced psoriasis exacerbation with autoimmune-mediated after COVID-19. Most patients had multiple areas of abnormal brain connectivity involving the frontal and parieto-temporo-occipital lobes, as well as the thalamus.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The whole body F-18 FDG PET can be a potential tool to assess inflammatory process and support the hyperinflammatory etiology, mainly for lesions in skeletal muscle, vascular wall, and lung, as well as, multiple brain abnormalities in post-acute COVID-19. Nonetheless, further studies are recommended to confirm the results.</AbstractText><CopyrightInformation>&#xa9; The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiatkittikul</LastName><ForeName>Peerapon</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7076-3829</Identifier><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Promteangtrong</LastName><ForeName>Chetsadaporn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunawudhi</LastName><ForeName>Anchisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siripongsatian</LastName><ForeName>Dheeratama</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siripongboonsitti</LastName><ForeName>Taweegrit</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckpanich</LastName><ForeName>Piyanuj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thongdonpua</LastName><ForeName>Supachoke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jantarato</LastName><ForeName>Attapon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piboonvorawong</LastName><ForeName>Chaiyawat</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonghoi</LastName><ForeName>Nirawan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chotipanich</LastName><ForeName>Chanisa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101530478</NlmUniqueID><ISSNLinking>1869-3474</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">F-18 FDG PET</Keyword><Keyword MajorTopicYN="N">Fluorodeoxyglucose</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19</Keyword><Keyword MajorTopicYN="N">Resting-state functional MRI</Keyword></KeywordList><CoiStatement>Competing InterestsPeerapon Kiatkittikul, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Dheeratama Siripongsatian, Taweegrit Siripongboonsitti, Piyanuj Ruckpanich, Supachoke Thongdonpua, Attapon Jantarato, Chaiyawat Piboonvorawong, Nirawan Fonghoi, and Chanisa Chotipanich declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>8</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35069924</ArticleId><ArticleId IdType="pmc">PMC8760088</ArticleId><ArticleId IdType="doi">10.1007/s13139-021-00730-6</ArticleId><ArticleId IdType="pii">730</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19, https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020; 2020 Accessed 30 Sept 2021.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;5. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O&#x2019;Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174:576&#x2013;578. doi: 10.7326/M20-5661.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27:258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez J-M, Andres M, Ramos JM, Arenas-Jim&#xe9;nez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82:378&#x2013;83. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4&#x2013;6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med Off Publ Soc Nucl Med. 2013;54:647&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">23359660</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N&#xe5;gren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103&#x2013;2110. doi: 10.1007/s00259-009-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1264-0</ArticleId><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana IC, Bongarzone S, Gee A, Souza DO, Zimmer ER. PET imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci. 2020;43:935&#x2013;938. doi: 10.1016/j.tins.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7580682</ArticleId><ArticleId IdType="pubmed">33131922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, et al. Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. 2021;48:3187&#x2013;3197. doi: 10.1007/s00259-021-05294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05294-3</ArticleId><ArticleId IdType="pmc">PMC7937050</ArticleId><ArticleId IdType="pubmed">33677642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging. 2021;48:1460&#x2013;1466. doi: 10.1007/s00259-020-05084-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05084-3</ArticleId><ArticleId IdType="pmc">PMC7595761</ArticleId><ArticleId IdType="pubmed">33123760</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823&#x2013;2833. doi: 10.1007/s00259-021-05215-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kas A, Soret M, Pyatigoskaya N, Habert M-O, Hesters A, Le Guennec L, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021;48:2543&#x2013;2557. doi: 10.1007/s00259-020-05178-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05178-y</ArticleId><ArticleId IdType="pmc">PMC7810428</ArticleId><ArticleId IdType="pubmed">33452633</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, Schr&#xf6;ter N, Bormann T, Thurow J, Wagner D, Frings L, et al. Altered regional cerebral function and its association with cognitive impairment in COVID-19: A prospective FDG PET study. J Nucl Med. 2021;62:41&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383:1757&#x2013;1766. doi: 10.1056/NEJMcp2009249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Slart RHJA. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250&#x2013;1269. doi: 10.1007/s00259-018-3973-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-3973-8</ArticleId><ArticleId IdType="pmc">PMC5954002</ArticleId><ArticleId IdType="pubmed">29637252</ArticleId></ArticleIdList></Reference><Reference><Citation>Besson FL, de Boysson H, Parienti J-J, Bouvard G, Bienvenu B, Agostini D. Towards an optimal semiquantitative approach in giant cell arteritis: an 18F-FDG PET/CT case-control study. Eur J Nucl Med Mol Imaging. 2014;41:155&#x2013;166. doi: 10.1007/s00259-013-2545-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2545-1</ArticleId><ArticleId IdType="pubmed">24008434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani SL, Samet J, Franz CK, Hsieh C, Nguyen CV, Horbinski C, et al. Musculoskeletal involvement of COVID-19: review of imaging. Skeletal Radiol. 2021;50:1763&#x2013;1773. doi: 10.1007/s00256-021-03734-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00256-021-03734-7</ArticleId><ArticleId IdType="pmc">PMC7889306</ArticleId><ArticleId IdType="pubmed">33598718</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschman T, Schneider J, Greuel S, Meinhardt J, Streit S, Goebel H-H, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol. 2021;78:948&#x2013;960. doi: 10.1001/jamaneurol.2021.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2004</ArticleId><ArticleId IdType="pubmed">34115106</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50:499&#x2013;511. doi: 10.1007/s11239-020-02230-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02230-4</ArticleId><ArticleId IdType="pmc">PMC7373848</ArticleId><ArticleId IdType="pubmed">32700024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Alfonso B, Ruiz Sol&#xed;s S, Silva-Hern&#xe1;ndez L, Pintos Pascual I, Aguado Ib&#xe1;&#xf1;ez S, Salas AC. 18F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316133</ArticleId><ArticleId IdType="pubmed">34340958</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamimoto R, Hotta M, Ishikane M, Inagaki T. FDG-PET/CT images of COVID-19: a comprehensive review. Glob Health Med. 2020;2:221&#x2013;226. doi: 10.35772/ghm.2020.01056.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2020.01056</ArticleId><ArticleId IdType="pmc">PMC7731428</ArticleId><ArticleId IdType="pubmed">33330811</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19&#x2014;a systematic review of the literature. J Autoimmun. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506. doi: 10.1016/j.jaut.2020.102506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102506</ArticleId><ArticleId IdType="pmc">PMC7296326</ArticleId><ArticleId IdType="pubmed">32563547</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijl JP, Kwee TC, Slart RHJA, Yakar D, Wouthuyzen-Bakker M, Glaudemans AWJM. Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia. Eur J Nucl Med Mol Imaging. 2021;48:1467&#x2013;1477. doi: 10.1007/s00259-020-05071-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05071-8</ArticleId><ArticleId IdType="pmc">PMC8113205</ArticleId><ArticleId IdType="pubmed">33106925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Chae BJ, Park WC, Kim JS, Kim SH, Jung SS, et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol. 2009;7:63. doi: 10.1186/1477-7819-7-63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7819-7-63</ArticleId><ArticleId IdType="pmc">PMC2732624</ArticleId><ArticleId IdType="pubmed">19664272</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin JT, Raley J, Tunbridge E, Lanary K, Floyer-Lea A, Narain C, et al. Functional asymmetry for auditory processing in human primary auditory cortex. J Neurosci. 2003;23:11516&#x2013;11522. doi: 10.1523/JNEUROSCI.23-37-11516.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-37-11516.2003</ArticleId><ArticleId IdType="pmc">PMC6740959</ArticleId><ArticleId IdType="pubmed">14684855</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel K, Bandelow B, Gruber O, Wedekind D. Neuroimaging in anxiety disorders. J Neural Transm. 2009;116:703&#x2013;716. doi: 10.1007/s00702-008-0077-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-008-0077-9</ArticleId><ArticleId IdType="pmc">PMC2694920</ArticleId><ArticleId IdType="pubmed">18568288</ArticleId></ArticleIdList></Reference><Reference><Citation>Su L, Cai Y, Xu Y, Dutt A, Shi S, Bramon E. Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry. 2014;14:321. doi: 10.1186/s12888-014-0321-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-014-0321-9</ArticleId><ArticleId IdType="pmc">PMC4240898</ArticleId><ArticleId IdType="pubmed">25407081</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, Schr&#xf6;ter N, Bormann T, Thurow J, Wagner D, Frings L, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021;62:910&#x2013;915. doi: 10.2967/jnumed.121.262128.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262128</ArticleId><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>